Profile data is unavailable for this security.
About the company
Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.
- Revenue in SEK (TTM)53.90m
- Net income in SEK-51.89m
- Incorporated2007
- Employees20.00
- LocationEnzymatica AB (publ)Ideon Science Park, Scheelevagen 19LUND 223 70SwedenSWE
- Phone+46 462863100
- Websitehttps://www.enzymatica.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRLAB Therapeutics AB | 57.46m | -110.01m | 145.79m | 31.00 | -- | 4.75 | -- | 2.54 | -1.75 | -1.75 | 0.8494 | 0.3617 | 0.4188 | -- | 11.05 | 1,853,613.00 | -80.18 | -31.73 | -328.93 | -40.78 | -72.94 | -33.99 | -191.45 | -101.39 | -- | -5.62 | 0.4937 | -- | -39.28 | -- | -32.34 | -- | -- | -- |
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 165.20m | 144.00 | -- | 0.3107 | 5.96 | 0.5649 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Isofol Medical AB (publ) | 0.00 | -54.17m | 199.59m | 6.00 | -- | -- | -- | -- | -0.246 | -0.246 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -50.03 | -- | -64.52 | -- | -- | -- | -1,377.23 | -- | -- | -- | -- | -- | -- | -24.56 | -- | -- | -- |
| Elicera Therapeutics AB | 10.86m | -17.41m | 299.46m | 2.00 | -- | 12.82 | -- | 27.59 | -0.4128 | -0.4128 | 0.2696 | 0.4813 | 0.3948 | -- | 5.80 | 5,427,590.00 | -63.31 | -46.13 | -78.88 | -59.33 | -- | -- | -160.35 | -270.46 | -- | -- | -- | -- | 52.28 | -- | -8.05 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -76.37m | 307.58m | 6.00 | -- | -- | -- | -- | -3.60 | -3.60 | 0.00 | -1.33 | 0.00 | -- | -- | 0.00 | -179.79 | -146.87 | -660.20 | -220.28 | -- | -- | -- | -1,379,275.00 | -- | -39.82 | 3.77 | -- | -- | -- | -49.32 | -- | -- | -- |
| Biohit Oyj | 167.48m | 28.80m | 323.34m | 46.00 | 13.95 | 2.53 | 8.91 | 1.93 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 7.65m | -14.71m | 405.97m | 12.00 | -- | 4.33 | -- | 53.06 | -0.5929 | -0.5929 | 0.3093 | 3.66 | 0.0792 | -- | 5.89 | 637,583.30 | -15.22 | -9.29 | -16.29 | -10.07 | 81.36 | 109.32 | -192.31 | -60.64 | -- | -- | -- | -- | -21.73 | 15.66 | 36.56 | -- | -35.49 | -- |
| Enzymatica AB (publ) | 53.90m | -51.89m | 475.76m | 20.00 | -- | 3.83 | -- | 8.83 | -0.2138 | -0.2138 | 0.2221 | 0.5116 | 0.3197 | 1.17 | 4.88 | 2,695,150.00 | -30.78 | -33.41 | -33.37 | -38.75 | 61.45 | 61.39 | -96.27 | -104.78 | -- | -108.60 | 0.0082 | -- | 18.27 | -13.49 | 2.42 | -- | -45.57 | -- |
| Navamedic ASA | 536.68m | -22.34m | 498.55m | 45.00 | -- | 1.57 | 67.18 | 0.929 | -1.11 | -1.11 | 26.97 | 13.93 | 0.9351 | 3.48 | 8.28 | -- | -3.89 | -0.5784 | -5.27 | -0.8691 | 38.97 | 39.81 | -4.16 | -0.5578 | 0.887 | 0.4484 | 0.384 | -- | 6.38 | 21.92 | -329.13 | -- | -- | -- |
| Moberg Pharma AB (publ) | 13.54m | -27.24m | 504.17m | 5.00 | -- | 0.7313 | -- | 37.24 | -0.5809 | -0.5809 | 0.289 | 14.15 | 0.0195 | 1.49 | 4.58 | 2,707,600.00 | -3.92 | -11.42 | -4.02 | -11.95 | 56.73 | -- | -201.18 | -1,423.72 | 14.49 | -- | 0.0038 | -- | 37.99 | -- | 89.32 | -- | -- | -- |
| Dicot Pharma AB | 200.00k | -80.10m | 599.79m | 4.00 | -- | 8.17 | -- | 2,998.94 | -0.0416 | -0.0416 | 0.0001 | 0.0365 | 0.0019 | 10.77 | 0.0305 | -- | -76.61 | -87.67 | -86.56 | -101.98 | -35,950.00 | -32,362.81 | -40,050.00 | -36,853.27 | 6.40 | -- | -- | -- | 669.23 | 57.45 | -39.00 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -65.17m | 654.81m | 10.00 | -- | 6.43 | -- | -- | -4.84 | -4.84 | 0.00 | 7.82 | 0.00 | -- | -- | -- | -32.48 | -26.32 | -47.29 | -29.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 52.40 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Enzymatica AB (publ)'s reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 42.60k | 0.02% |
Data from 30 Dec 2025 - 30 Dec 2025Source: FactSet Research Systems Inc.
